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ABSTRACT 
MORGAN ELIZABETH DAVIS: The Effect of Sumatriptan on Clinically Relevant 
Behavioral Endpoints in a Recurrent Nitroglycerin Migraine Model in Rats 
(Under the direction of Dr. Kenneth Sufka) 
 
 
The present research sought to determine the effects of sumatriptan on 
clinically relevant behavioral endpoints in migraine produced by repeated 
nitroglycerin (NTG) administrations in rats.  Rats were given 5 NTG administrations 
each of which was followed by either saline, 0.3 mg/kg sumatriptan, or 1.0 mg/kg 
sumatriptan over a 2-week period.  During their 5th NTG migraine episode, 
behavioral endpoints were the Rat Grimace Scale, photophobia, and movement.  
Sumatriptan dose dependently attenuated a) loss in weight, b) elevated Rat Grimace 
Scale pain scores, and c) decreased movement in the modified light-dark box.  In 
addition, rats with the highest dose of sumatriptan tended to spend more time in the 
light portion of the light-dark box.  We conclude from this study that sumatriptan is 
effective in reversing behavioral endpoints that parallel clinical symptoms of human 
migraineurs.  These findings further validate the recurrent NTG migraine model as a 
clinically relevant simulation of human migraine that can be used as a drug-
screening tool for novel therapeutics. 
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1. Introduction 
 
 
Migraine is a common incapacitating neurobiological headache disorder 
affecting about 28 million Americans (Silberstein, 2004).  In addition, 11% of the 
overall population in the United States and Western Europe has significant problems 
with migraine headache (Goadsby, Lipton, & Ferrari, 2002).  Women show an 
increased incidence of migraine with 18% of women affected compared to 6% of men 
(Goadsby, Lipton, & Ferrari, 2002).  Migraine is best understood as a form of 
neurovascular headache involving the dilation of blood vessels, which subsequently 
causes pain and triggers further nerve activation (Goadsby, Lipton, & Ferrari, 2002).  
The typical throbbing that occurs during a migraine attack is commonly aggravated 
by movement and accompanied by hypersensitivity to light (photophobia).  Other 
symptoms of migraine include nausea, diarrhea, sensitivity to sound, anxiety, and 
depression (Silberstein, 2004).   
Migraine attacks in humans greatly affect the quality of life and are severely 
debilitating in that of the 90% of migraineurs who report moderate or severe pain, 
three-quarters have reduced ability to function during the headache attacks and one-
third require bed rest (Lipton et al, 2007).  Migraine is also extremely costly in that 
each migraineur is estimated to lose 6.6 workdays per year due to absenteeism or 
reduced work productivity (Leonardi et al, 2010).  Because of the high prevalence of 
migraine, this loss of productivity totals to 25-million lost workdays per year in the 
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United Kingdom, and migraine’s yearly cost to employers reaches 13 billion dollars 
(World Health Organization, 2012; Silberstein, 2004).  Moreover, the World Health 
Organization reports migraine as the 19th most common cause of disability in men 
and women of all ages (Leonardi et al, 2010). 
Different from a typical “bad headache,” migraine episodes are usually made 
up of four phases (premonitory, aura, headache, and resolution) characterized by a 
combination of neurological, gastrointestinal, and autonomic changes (Silberstein, 
2004).  The onset of migraine attacks are commonly marked by a premonitory phase 
which consists of predictable symptoms such as changes in mood, pain in the neck 
and back, flu-like symptoms, phonophobia (hypersensitivity to sounds), and/or 
fatigue that may occur hours to days before an attack (Bigal et al, 2009).  For some 
individuals, premonitory symptoms are then followed by periods of “aura” in which 
migraineurs experience unusual changes in vision, sensation, speech, or movement 
lasting from 5 to 50 minutes (Silberstein, 2004).  The headache phase of a migraine 
attack consists of the gradual onset of moderate to severe, typically unilateral 
throbbing pain lasting anywhere from 4 to 72 hours that is aggravated by movement.  
The resolution phase occurs after the headache and consists of a wide range of events 
including irritability, exhaustion, mood changes, euphoria, depression and/or malaise 
(Silberstein, 2004).   
Migraine can be classified as either episodic or chronic.  Formal diagnostic 
criteria for episodic migraine requires a minimum of five recurrent episodes with a 
combination of features that can vary among attacks (Silberstein, 2004).  On the other 
hand, chronic migraine is classified as 15 or more headache days per month 
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continuing for at least 3 months (Katsarava et al, 2012).  In addition, two subtypes of 
migraine are recognized, migraine with and without aura.  Migraine with aura 
requires the presence of at least one neurological aura symptom that gradually 
develops and persists anywhere from 4 to 60 minutes followed by migraine (Ferrari, 
1998).  Migraine without aura, however, accounts for the majority of reported 
migraine episodes totaling for 75% of migraineurs (Ferrari, 1998).  Despite 
significant efforts, migraine remains substantially under-diagnosed and undertreated 
(Leonardi et al, 2010).   
Once an individual has been diagnosed, two standard methods of 
pharmacotherapy are available.   Prophylactic, or preventative, treatments aim to 
reduce the severity and occurrence of migraine attacks.  Common preventative 
treatments include beta-blockers, tricyclic antidepressants, and anticonvulsants 
(Silberstein, 2004).  However, several of these drugs are compounded with adverse 
side effects and only moderate efficacy.  As a result, only 13% of migraineurs report 
taking this route of action (Lipton et al, 2007).   
The second method is acute treatments such as triptans, ergots, analgesics, and 
opioids, which attempt to abort or reverse a headache following the onset of a 
migraine episode.  The use of triptans has resulted in a time of remarkable progress in 
pain modulation and treatment of migraine (Bigal et al, 2009).  Triptans are effective 
in that they alter blood flow in the brain (Humphrey et al, 1990).  In addition to 
relieving headache, triptans also contribute by relieving both nausea and vomiting, 
two symptoms frequently associated with migraine (Silberstein, 2004).  Effectiveness 
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of triptans is greatly enhanced by early detection of migraine and fast administration 
of the drug.  
The gold standard and first triptan to be used in treating migraine post onset is 
sumatriptan.  There are several routes of sumatriptan administration available 
including oral, intranasal, suppository, and subcutaneous.   Meta-analysis of 
subcutaneous sumatriptan, however, yields the most effective results showing that 
71% of patients report improvement in headache severity to mild or no pain within 1 
hour of the injection along with a therapeutic gain of 51% (Ferarri et al, 2001).   
Although acute migraine treatments are moderately effective in alleviating or 
reducing pain associated with migraines, predicting the onset of headache is often 
extremely difficult, especially for patients who do not experience premonitory 
symptoms or aura prior to their migraine attack.  In addition, current available 
migraine treatments are ineffective or poorly tolerated in millions of migraine patients 
collectively referred to as non-responders (Pradhan et al 2014).  As a result, current 
migraine therapies remain extremely limited, leaving room for improvement in drug 
discovery and clinical efficacy.   
 Animal models represent experimental conditions produced in one species for 
the purpose of studying and understanding similar phenomena that occurs in another 
species (Willner, 1991).  Because it is not always possible to study behaviors and 
disorders in human subjects, animal models provide a comparative mechanism for 
understanding and expanding upon existing knowledge of human behavior and its 
underlying processes (Van der Staay, 2006). When constructed and utilized 
efficiently, animal models attempt to simulate a symptom of a disorder, a group of 
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symptoms, or even a complete syndrome by addressing the etiology, treatment, 
physiological basis, and/or physiological mechanisms underlying successful treatment 
(Willner, 1991).   
Animal models of human behavior should also demonstrate three types of 
validity.   Predictive validity of an animal model shows that performance on a test 
accurately represents the predicted performance in the human condition being 
modeled.   Predictive validity of a behavioral model is often addressed by testing an 
animal’s response to clinically effective therapeutic drugs.  Face validity assesses the 
similarity between an animal model and the disorder it simulates.  This type of 
validity compares drug effects achieved in the model to comparable effects seen 
clinically.  Because a given condition may vary between species, construct validity 
analyzes the degree of homology and significance between an identified variable 
relevant to the clinical condition and a behavior in the animal simulation.  According 
to Van der Stay, to be useful, animal models should be testable, generalizable to 
humans, and provide a simplification of complex phenomena occurring in the clinical 
syndrome (Van der Staay, 2006).   
One of the main difficulties in improving treatments for migraine is the 
absence of predictive animal models (Pradhan et al, 2014).  The development of a 
valid animal model that accurately reflects clinically relevant endpoints of human 
migraine is essential for pre-clinical drug screenings to identify novel anti-migraine 
treatments and to gain an overall better understanding of migraine pathophysiology. 
Nitroglycerin (NTG) administration in human subjects is a common 
experimental paradigm that produces headache in normal individuals and a delayed 
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migraine without aura analogous to environmentally triggered migraines in migraine 
patients (Pradhan et al, 2014; Iversen, 2001).   The mechanism behind NTG induced 
migraine pain is believed to be the result of vasodilation of cranial blood vessels 
along with direct activation of pathways involved in nociception (Bates et al, 2010).  
NTG induced migraine attacks have since been reproduced in rodents in the attempt 
to create a valid rodent model of migraine (Iversen, 2001).  These studies, however, 
mainly focus on two clinically irrelevant endpoints, hyperalgesia and allodynia. 
One study examining the effects of acute and chronic restraint stress on pain 
response after NTG administration revealed that NTG produced hyperalgesia, or a 
heightened pain response to an already painful stimulus, after 2 and 4 hours.  A tail-
flick test was used as a measure of pain and NTG induced hyperalgesia was 
determined by the latency of response (Costa et al, 2005).  Although the previous 
study may be useful in understanding acute and chronic stress models, hyperalgesia is 
associated with nonspecific pain and is rarely seen in human migraineurs.  As a result, 
hyperalgesia is a clinically irrelevant endpoint in establishing a valid animal migraine 
model. 
A second study demonstrated dose dependent NTG induced thermal and 
mechanical allodynia, or a heightened pain response to non-painful stimulus in mice, 
30 to 60 minutes following NTG administration (Bates et al, 2010).  Mice were 
injected intraperitoneally (IP) with various doses of NTG followed by assays of 
thermal pain thresholds using the Hargreaves test and mechanical thresholds using a 
von Frey apparatus.  This study not only reported a significantly lower threshold to 
pain following NTG administration of 5 mg/kg and 10 mg/kg, but the anti-migraine 
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drug sumatriptan successfully reduced both thermal and mechanical hypersensitivity 
at 90 and 120 minutes (Bates et al, 2010).   
Although allodynia is a common symptom of chronic migraine and is more 
clinically relevant than hyperalgesia in modeling chronic migraine, this measure 
remains useless when modeling episodic migraine (Marcelo et al, 2009).  
Additionally, according to the diagnostic criteria for diagnosing migraine, neither 
chronic nor episodic migraine can be achieved clinically by a single episode.   The 
previous study only examined the effects of a single NTG administration at various 
doses; therefore, the discovery of NTG-induced allodynia is not consistent with the 
clinical description of migraine symptoms (Marcelo et al, 2009).   
Clinically relevant endophenotypes are necessary for a valid animal model of 
human migraine.  Endophenotypes are observable, disease-specific behavioral, 
biochemical, endocrinological, and neuroanatomical characteristics (Van der Staay, 
2006).  Since hyperalgesia and allodynia do not seem to accurately model 
endophenotypes or clinical symptoms of migraine, previous work from this 
laboratory attempted to validate more clinically relevant migraine behavioral 
endpoints.   
The first study analyzed the effects of a single NTG induced migraine episode 
on behavioral endophenotypes present in human migraine including pain, 
photophobia, sensitivity to movement, and peripheral allodynia (Staszko, 2014).  Rats 
were IP administered 10 mg/kg NTG and assays were performed 2 hours post 
injection.  Presence of pain was assayed using the Rat Grimace Scale, photophobia 
was monitored using a modified light-dark box, sensitivity to movement was assayed 
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using the modified light-dark box and Rotor-Rod, and peripheral allodynia was 
detected by a thermal tail-flick test.  Although NTG animals showed slightly higher 
pain scores with marginal significance compared to control animals, presence of 
photophobia was not evident.  Surprisingly, NTG animals showed less sensitivity to 
movement and actually had higher movement scores compared to control animals in 
both the modified light-dark box and Rotor-Rod test (Staszko, 2014).  This study also 
utilized a single NTG administration producing a single migraine attack, which is 
problematic because human clinical diagnosis specifically requires a minimum of 5 
recurrent episodes.  This study suggested that multiple NTG administrations were 
necessary to simulate and produce clinically relevant behavioral endophenotypes 
associated with NTG induced migraine in rats.   
The second study sought to accurately model the etiology and parallel 
clinically relevant symptoms of human migraine.  To correct the etiology, a recurrent 
NTG induced migraine model was developed using both 3 NTG and 5 NTG 
administrations (Johnson, 2014).   The various NTG administrations were necessary 
in determining the relationship between 5 migraine episodes in humans and the 
number of episodes required to produce clinically relevant endpoints in rats.  
Movement and photophobia were both measured using a modified light-dark box, 
pain was analyzed using the Rat Grimace Scale, and thermal tail dip tests determined 
peripheral allodynia.  In addition, this study sought to determine whether or not 
multiple migraine episodes in rats could produce chronic comorbidity of anxiety and 
depression relevant to human migraineurs.  The elevated plus maze and force swim 
tests were used to assay anxiety and depression behaviors.   
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Although analysis of pain scores using the Rat Grimace Scale failed to reveal 
significant differences among treatment groups, multiple NTG administrations 
significantly decreased time spent in the light chamber of the modified light-dark box, 
indicating photophobia; and significantly decreased movement indicating sensitivity 
to movement.  Another measure that was not originally specifically tested was 
changes in weight.  Animals receiving multiple NTG administrations gained 
significantly less weight compared to control animals, indicating the presence of 
nausea (Johnson, 2014).  The thermal tail flick test did not produce any observable 
differences in latency signifying peripheral allodynia among treatment groups and the 
anxiety-depression assays also failed to show significance.   
The previous recurrent NTG migraine model using 5 NTG administrations 
demonstrated the most drastic effects on photophobia, sensitivity to movement, and 
nausea compared to control animals; however, both 3 and 5 NTG doses failed to 
reveal any changes in allodynia or comorbidity of anxiety and depression (Johnson, 
2014).  These results suggest that the clinically relevant endpoints demonstrated in 
this study using 5 NTG administrations are sufficient and effective in modeling 
episodic migraine, but not chronic migraine. 
The previous study established predictive validity in that the recurrent NTG 
induced migraine model illustrated performance on the modified light-dark box test 
that accurately represented the photophobia and sensitivity to movement reported in 
the human condition.  To further validate the previous recurrent NTG induced 
migraine rodent model, in the present study, we sought to examine the effects of the 
commonly used acute migraine drug, sumatriptan, on a 5 NTG- induced migraine 
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model.  All animals were treated with 5 NTG administrations.  To illustrate a drug 
effect, we developed three conditions in which animals received saline, 0.3 mg/kg 
sumatriptan, or 1.0 mg/kg sumatriptan 30 minutes after each NTG injection.  Animals 
were assayed for the presence of pain, photophobia, and sensitivity to movement 2-
hours after the 5th NTG administration.   The Rat Grimace Scale was used to quantify 
pain in rat’s facial expressions and movement and photophobia were simultaneously 
measured using the modified light-dark box.  Changes in weight were also recorded 
for each animal over the 2-week experimental period.  Sumatriptan administration 
was hypothesized to dose-dependently reverse NTG migraine induced nausea, pain, 
photophobia, and sensitivity to movement evident in control animals.  As a result, we 
predict that sumatriptan treated animals will maintain body weight, display lower pain 
scores quantified by the Rat Grimace Scale, spend more time in the light chamber of 
the modified light-dark box, and move more in the modified light-dark box compared 
to untreated animals experiencing migraine. 
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2. Materials and Methods 
 
 
2.1. Animals 
 
 Experiments were conducted using 30 adult male Sprague-Dawley rats 
(Harlan Laboratories, Indianapolis, IN, USA) initially weighing between 260 and 330 
g.  Two rats were housed per cage at 22° C on a 12-hour light/dark cycle.  The bases 
of the cages were clear and plastic (Ancare) with dimensions 22.4 x 21.0 x 13.3 cm.  
Food (Teklad 7001, Teklad Diets, Madison, WI, USA) and water were available ad 
libitum via a wire lid placed on top of each cage.  Additionally, each cage was given a 
single, circular enclosure made of PVC end caps, measuring 16.5 cm in diameter, 7.5 
cm in height, and containing an arched opening.  These “huts” were used to permit 
rats to avoid light during the NTG migraine episodes experienced in their home 
cages.  All procedures were approved by the University of Mississippi IACUC 
(protocol number 13-023). 
 
2.2. Experimental Design and Procedures 
 
Previous studies demonstrated that 5 recurrent NTG administrations in the rat 
produced more clinically relevant end points than a single NTG dose, making it a 
more valid model for human migraine.  As a result, all animals in the current study 
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received 5 exposures of NTG intraperitoneally (IP) across a 2-week period.  To 
illustrate a drug reversal effect this study involved three experimental conditions in 
which rats received saline, 0.3 mg/kg sumatriptan, or 1.0 mg/kg sumatriptan 30 
minutes after each NTG injection.  Pilot studies performed by Bates et. al report that 
NTG induced thermal and mechanical allodynia in mice begin 30-60 minutes 
following IP injection, which helped to determine the 30 minute time interval used in 
this study.  10 rats were assigned to each treatment group and each cage, containing 
two rats, received the same treatment in order to minimize stress and other 
disturbances that could occur in pair housed animals.  On each treatment day, rats 
were placed on a scale and their weights were recorded prior to NTG administration.  
On the 5th treatment day, tests were run 2 hours post NTG administration and 1.5 
hours post saline or sumatriptan administration.  The assays performed were the Rat 
Grimace Scale, immediately followed by the modified light/dark box. 
 
2.2.1. Drug Administration 
 
 
 
All injections were administered to rats IP, with the second injection 
administered on the opposite side of the animal’s body relative to the first.  The 
concentration of NTG (Copperhead Chemical Company Inc., SDM®27, Tamaqua, 
PA, USA) used was 5 mg/kg/ml dissolved in a 50% ethanol/50% propylene glycol 
solution.  In order to achieve a final NTG dose of 10 mg/kg, a 2 ml volume of NTG 
was administered per kg body weight (10 mg/kg/2 ml).  The original 6mg/0.5 ml 
preparation of injectable sumatriptan succinate (PAR Pharmaceutical, Woodcliff 
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Lake, New Jersey, USA) was diluted using physiological saline to attain experimental 
concentrations of 0.3 mg/kg and 1.0 mg/kg. 
 
2.2.2. Rat Grimace Scale 
 
 The Rat Grimace Scale is a partially automated method designed to quantify a 
rat’s pain state by observing facial expressions (Sotocinal et al., 2011).  Rats were 
placed in a clear Plexiglas chamber with a wire base measuring 31.1 cm x 21.6 cm x 
26.0 cm and allowed to move freely throughout the apparatus.  A dry-erase board was 
placed behind the chamber to identify each subject.  Headshot pictures containing 
clear images of the face, ears, and whiskers were taken of each rat using a 16 GB iPad 
mini 5-megapixel iSight Camera with Retina display 2 hours post NTG.  After 
pictures were obtained, each rat was transferred back to its cage, and the chamber was 
cleaned out using Clorox wipes before the next subject was tested.  Operational 
definitions and guidelines outlined in studies performed by Sotocinal et al. were used 
to train individuals to analyze pictures of each subject and determine subsequent pain 
scores.  Scorers viewed images, one at a time, using a Microsoft Powerpoint slide 
show.  Pictures were randomized and identifications were removed in order to rate 
each animal blindly.   
 
For each photo, pain scores of 0,1, or 2 where assigned to quantify pain in 
four categories, or action units.  A score of  “0” was given in a situation where the 
scorer was highly confident that the action unit was absent.  A pain score of “1” 
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showed high confidence of moderate appearance of the characteristic and a score of 
“2” indicated high confidence in the obvious appearance of the action unit (Sotocinal 
et al., 2011).  The four action units demonstrated by rats in pain included 1) orbital 
tightening (partial/complete eye closure), 2)  nose/cheek flattening (disappearance of 
the crease between cheek and whisker pads), 3) ear changes (ears fold and angle 
forwards or outwards resulting in a pointed shape), and 4) whisker changes (whiskers 
move forward, away from the face and stand on end).  Scores were averaged from 
two raters, with 72% agreement, to produce an overall pain score for each rat. 
 
2.2.3. Modified Light-Dark Box with Movement 
 
 The modified light-dark box was used to quantify avoidance of light and 
diminished motor activity, two measures commonly associated with episodes of 
migraine in humans.  This device was a modified version of a conditioned place 
preference (CPP) apparatus (Model #ENV-013, Med Associates Inc., St. Albans, VT, 
USA).  The CPP box was customized for this experiment by covering the tops of the 
black and grey chambers, which are normally clear, with dark construction paper to 
prevent light from coming into these sections.  The white chamber was left unaltered 
so that light could freely pass through the clear lid.  This created a distinct light and 
dark environment that rats could freely move throughout during testing.   Following 
Rat Grimace pictures, rats were transferred to the grey middle chamber of the 
modified light-dark box.  The doors of the grey chamber remained closed for one 
minute to allow each animal to acclimate to their new environment.  After the 
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acclimation time ceased, the chamber doors allowing access to the black and white 
chambers were simultaneously opened, and the testing session proceeded for 10 
minutes.  Throughout the 10-minute interval, total movement throughout the 
apparatus was recorded as well as the amount of time spent in the white (light) 
chamber and the time spent in the black and grey boxes, collectively referred to as the 
dark chamber.  The modified apparatus was cleaned using a Clorox wipe in between 
each subject tested. 
 
2.3. Statistical Analysis and Dependent Measures 
 
 Data collected was analyzed by one-way ANOVA using SPSS software.  
Planned comparisons were performed with Fisher’s LSD and statistical significance 
set at p<0.05.  Previous work in the validation of a recurrent NTG migraine model in 
the rat determined the dependent measures to be examined.  These variables included 
percent change in weight, Rat Grimace Scale overall pain scores, time spent in the 
light chamber of the modified light-dark box, and degree of movement recorded by 
the modified light-dark box. 
 
 
 
 
 
 
	   16	  
 
 
 
3. Results 
 
 The effects of sumatriptan on NTG induced weight changes over the 2-week 
injection period are summarized in Figure 1.  Sumatriptan dose dependently induced 
a change in percent weight gain compared to animals receiving saline.  The control 
group lost about 3% of their original weight, while rats receiving 0.3 or 1.0 mg/kg 
sumatriptan either maintained or gained approximately 2% of their original body 
weight.  These data were analyzed using a one-way ANOVA that revealed a main 
effect that approached significance, F(2,24)= 2.62, p=0.094.  Planned comparisons 
using Fischer’s LSD revealed that the mean percent weight change of the 1.0 
sumatriptan group was significantly more than the saline control group (p<0.033). 
 The effects of sumatriptan on NTG induced modifications in the Rat Grimace 
Scale pain scores are summarized in Figure 2.  Treatment with both 0.3 and 1.0 
mg/kg sumatriptan reduced overall pain scores compared to animals receiving saline.  
Consistent with these observations, a one-way ANOVA revealed a significant main 
effect, F(2,24)= 6.23, p=0.007.  Planned comparison analysis also revealed that the 
mean RGS scores for both the 0.3 and 1.0 sumatriptan groups were significantly 
lower than the saline group (p< 0.006 - 0.005). 
 
	   17	  
The effects of sumatriptan on movement are summarized in Figure 3.  
Sumatriptan dose dependently increased average movement scores during the 
modified light-dark box testing periods.   These data were analyzed using a one-way 
ANOVA variance that revealed a main effect that approached significance, F(2,24)= 
2.397, p=0.112). Planned comparisons using Fisher’s LSD showed that animals 
treated with 1.0 mg/kg sumatriptan had significantly higher mean movement scores 
compared to saline animals (p<0.045). 
 The effects of sumatriptan on time spent in the light chamber of the modified 
light-dark box are summarized in Figure 4.  Treatment with 1.0 mg/kg sumatriptan 
produced an upward trend suggesting an increase in the amount of time spent in the 
light chamber.  A one-way ANOVA variance of these data, however, failed to reveal 
a significant treatment effect, F(2,24)= 0.636, p=0.53.  Further analysis using 
Fischer’s LSD planned comparisons also failed to reveal significant group differences 
(p=n.s).  
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4. Discussion 
 
 The current study sought to expand upon the recurrent NTG rodent model of 
migraine by replicating clinically relevant endpoints of human migraine demonstrated 
by the Johnson (2014) study and to show a drug reversal using sumatriptan.  The 
endpoints relevant to migraine and its sensitivity to sumatriptan include weight loss, 
presence of pain, movement, and photophobia.  Rats were administered 5 NTG 
injections each followed by saline, 0.3 mg/kg sumatriptan, or 1.0 mg/kg sumatriptan 
and then clinically relevant dependent measures were assessed during the 5th migraine 
episode using the Rat Grimace Scale and the modified light-dark box.   
 When comparing changes in body weight in NTG control and sumatriptan 
animals, NTG animals showed a slight decrease in mean body weight.  These 
findings are consistent with the Johnson (2014) study that demonstrated that 5 NTG 
migraine episodes produced a significantly lower body weight than vehicle treated 
animals over the same 2-week period.  In the Johnson study, rats showed a slower 
weight gain rather than the loss of weight experienced by rats in the present study.  
This difference, however, reflects the difference in weight and younger age of test 
animals that were approximately 100 grams lighter and in a steeper growth curve in 
the Johnson study.  
The sumatriptan manipulation in animals dose dependently reversed changes 
in weight by increasing weight gain with 1.0 mg/kg sumatriptan administration 
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having the strongest affect.  One of the common symptoms in human migraine is 
nausea. Experiencing nausea subsequently causes people to eat less and may 
ultimately result in changes in body weight, specifically weight loss in migraineurs.  
As a result, we interpret the previous findings along with the findings of the present 
research to suggest that the loss in body weight (or failure to gain weight) is likely 
related to NTG induced nausea that alters food consumption and impedes weight gain 
in rats.  The reversal of migraine induced weight loss and nausea by sumatriptan 
parallels the clinical picture and effects of acute treatment in humans.  To our 
knowledge this is the first report that sumatriptan alters this clinically relevant 
endpoint in rats.  
 Since the most common and defining aspect of migraine is headache pain, 
NTG induced pain was quantified using pain scores generated by the Rat Grimace 
Scale (RGS) (Sotocinal et al, 2011).  Since nonverbal infants express pain using facial 
expressions, the idea behind this test is that rats experiencing migraine pain would 
display higher pain scores when rated based off of their facial features using RGS.  
Both sumatriptan treated groups displayed lower overall pain scores than control 
animals, suggesting that they were in a lower overall pain state.   
Raters used in the present study quantified pain scores for the 5 NTG control 
animals in the 0.5 range, which was slightly higher than previously reported by 
Johnson et al.  Presence of pain in sumatriptan animals, however, was significantly 
lower.  These results suggest that sumatriptan may mitigate the effects of NTG 
induced migraine by lowering pain scores on the Rat Grimace Scale.  To our 
knowledge, this is the first case in which sumatriptan has been reported to lower this 
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behavioral index of migraine related to pain quantified by facial expressions.   In 
addition, these findings along with the similar results from the previous work in this 
lab indicate the reliability of this assay as a measure of pain during NTG migraine 
episodes and its attenuation with appropriate treatment.  
 Although pain scores generated by the present research are significantly lower 
than RGS scores from the original Sotocinal et al. study, this was expected due to the 
fact that pain from a NTG migraine episode is moderate compared to the types of 
pain assayed by Sotocinal et al.  The Sotocinal study assayed spontaneous pain that 
reached the test’s upper limit of 2.  As a result, the pain assays reported by Sotocinal 
et al. appear to be a more severe type of pain than that produced by an NTG induced 
migraine episode. 
 In the human clinical profile, physical activity often exacerbates pain during a 
migraine episode.  As a result, migraineurs avoid or minimize unnecessary 
movement.  The current study replicated the previous finding of NTG migraine 
induced sensitivity to movement in that 5 NTG migraine episodes produced 
movement scores using the modified light-dark box comparable to those seen in the 
Johnson et al study.  Additionally, our drug manipulation using sumatriptan dose-
dependently increased movement scores compared to NTG saline animals, suggesting 
the attenuation of NTG migraine induced movement sensitivity due to migraine pain.  
The predictability of this behavioral endpoint under NTG migraine and treatment 
conditions parallels the human clinical condition and provides additional validity to 
our recurrent NTG migraine rodent model. 
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  The typical throbbing that occurs during a migraine attack is also commonly 
accompanied by photophobia (Silberstein, 2004).  To assess this in our model, time 
spent in the light portion of the modified light-dark box was measured.  We predicted 
that animals experiencing migraine would mimic the human condition by avoiding 
the light portion of the apparatus.  This study showed that under the highest 
sumatriptan dose animals did tend to spend more time in the light portion of the 
modified light-dark box, but this effect was not statistically significant.  
 The previous finding can be interpreted in two ways.  The first suggests that 
the predicted effect was not evident under the current method created to test for 
photophobia in this study.  The light source used was simply ambient light in the 
room coming into the box with the clear lid.  Adjusting the lighting parameters and 
creating a brighter environment inside of the light box with greater sensitivity to light 
may result in a significant reversal of photophobia among sumatriptan treated 
animals. 
The second theory suggests variability in efficacy rather than the need to alter 
lighting parameters in the current testing procedure.  Given that only 71% of 
migraineurs report improvement with sumatriptan (51% therapeutic gain), we expect 
to have some non-responders, just like in the clinical situation (Ferrari et al, 2001).  It 
is interesting to note, that among rats in the 1.0 mg/kg sumatriptan group, those that 
displayed higher RGS scores spent less time in the light portion of the light-dark box, 
and this correlation was -0.70.  Consequently, we believe our NTG migraine animal 
simulation demonstrates the limited efficacy of current anti-migraine drugs in some 
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non-responders and thus correctly models the clinical picture on this dependent 
measure as well.     
 Another reported symptom associated with human migraine is diarrhea 
(Silberstein, 2004).  One unexpected finding from the current study that mirrors the 
clinical picture is the presence of diarrhea.  Although it was not systematically 
quantified, researchers noticed NTG saline animals having an unusual amount of 
diarrhea in their home cages following migraine attacks.  These observations were not 
seen in sumatriptan treated animals.  We believe that this measure might be 
associated with the significant amount of weight loss that we interpreted as nausea 
found among NTG saline animals experiencing migraine.  Although this behavioral 
aspect was not systematically quantified across treatment conditions in the present 
study, this finding suggests that it might be a clinically relevant endpoint in 
determining the effectiveness of sumatriptan on NTG induced migraine and in future 
testing of drug efficacy.   
The recurrent 5 NTG migraine model demonstrates two clinically relevant 
behavioral endpoints for migraine: sensitivity to movement and photophobia.  Other 
noteworthy homologies demonstrated in NTG migraine induced animals are evidence 
of pain expression indicated by Rat Grimace pain scores and loss of weight, which 
was interpreted as nausea.  In addition, our model shows a drug reversal effect of the 
previous behavioral endpoints using one of the most common pharmacotherapeutics 
in migraine treatment, sumatriptan.   Clinical validation of an animal model requires 
the presence of several homologies between the animal model and the human 
condition, which we believe to be evident in the present NTG migraine model.  Since 
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the present model provides predictive validity and response to clinically effective 
drugs, this recurrent NTG migraine model is a valid simulation of human migraine 
and can be used as a broad screening tool to develop novel anti-migraine treatments. 
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Figure 1. Mean percent weight gain as a function of treatment group in rats on their 
5th NTG migraine episode.  Bars represent group means +/- SEM.  NTG +Saline 
animals show a slight decrease in weight compared to animals receiving 0.3 or 1.0 
mg/kg sumatriptan.  Animals receiving the high dose of sumatriptan gained more 
weight over the two week injection period compared to NTG + saline animals, 
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suggesting diminished nausea and increased appetite (p<0.033).  Sample sizes were 
n=8-10. 
 
 
 
 
 
 
Figure 2.  Mean Rat Grimace Scale pain scores as a function of treatment group in 
rats on their 5th NTG migraine episode.  Bars represent group means +/- SEM.  Both 
0.3 mg/kg and 1.0 mg/kg doses of sumatriptan decreased overall pain scores 
quantified via rat’s facial expressions in pictures taken during Rat grimace testing 
compared to NTG + saline group.  Results indicate attenuation of pain associated with 
migraine following treatment with sumatriptan (p<0.006-0.005).  Sample sizes were 
n=8-10. 
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Figure 3. Mean movement (number of beam breaks) in the modified light-dark box as 
a function of treatment group in rats on their 5th NTG migraine episode.  Bars 
represent group means +/- SEM.  The correct upward trend was seen for both 
administration of 0.3 and 1.0 mg/kg sumatriptan.  Movement was significantly 
increased by administration of 1.0 mg/kg sumatriptan compared to NTG + saline 
animals, indicating reversal of NTG induced movement sensitivity (p<0.045).  
Sample sizes were n=8-10. 
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Figure 4. Mean time spent in the light chamber of the modified light-dark box as a 
function of treatment group in rats on their 5th NTG migraine episode.  Bars represent 
group means +/- SEM.  Treatment with sumatriptan following NTG produced a 
modest increase in time spent in the light chamber (p= n.s.).  Sample sizes were n=8-
10. 
 
 
